BR0112292A - Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto - Google Patents

Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto

Info

Publication number
BR0112292A
BR0112292A BR0112292-4A BR0112292A BR0112292A BR 0112292 A BR0112292 A BR 0112292A BR 0112292 A BR0112292 A BR 0112292A BR 0112292 A BR0112292 A BR 0112292A
Authority
BR
Brazil
Prior art keywords
compound
treating
pharmaceutical composition
thromboembolic disorders
preventing thromboembolic
Prior art date
Application number
BR0112292-4A
Other languages
English (en)
Inventor
Donald J P Pinto
Mimi L Quan
Francis J Woerner
Renhua Li
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of BR0112292A publication Critical patent/BR0112292A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR OU PREVENIR DISFUNçõES TROMBOEMBóLICAS E USO DE UM COMPOSTO". O presente pedido de patente descreve heteroaril-fenil heterobibiciclos e seus derivados, ou formas de sal farmaceuticamente aceitável do mesmo, que são úteis como inibidores do fator Xa.
BR0112292-4A 2000-06-23 2001-06-22 Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto BR0112292A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21403200P 2000-06-23 2000-06-23
PCT/US2001/020113 WO2002000655A1 (en) 2000-06-23 2001-06-22 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
BR0112292A true BR0112292A (pt) 2003-06-24

Family

ID=22797508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112292-4A BR0112292A (pt) 2000-06-23 2001-06-22 Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto

Country Status (14)

Country Link
US (1) US6506771B2 (pt)
EP (1) EP1296982B1 (pt)
JP (1) JP2004501918A (pt)
CN (1) CN1439008A (pt)
AT (1) ATE373655T1 (pt)
AU (1) AU2001268712A1 (pt)
BR (1) BR0112292A (pt)
CA (1) CA2410393A1 (pt)
DE (1) DE60130555T2 (pt)
ES (1) ES2290150T3 (pt)
IL (1) IL152916A0 (pt)
MX (1) MXPA02012895A (pt)
NZ (1) NZ523184A (pt)
WO (1) WO2002000655A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
WO2002085353A1 (en) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones as factor xa inhibitors
AU2003273179A1 (en) * 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
ES2263058T3 (es) 2002-08-19 2006-12-01 Glaxo Group Limited Derivados de pirimidina como inhibidores selectivos de cox-2.
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2558848C (en) 2004-03-05 2013-11-19 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
JP4738419B2 (ja) * 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN103242310A (zh) * 2012-02-10 2013-08-14 苏州迈泰生物技术有限公司 吡唑并吡啶酮类化合物及其在制备抗凝血药物中的用途
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
GB201321749D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015188051A1 (en) * 2014-06-06 2015-12-10 Biogen Ma Inc. Atx modulating agents
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2240946C (en) * 1995-12-21 2002-09-10 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor xa inhibitors
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
JP2001509145A (ja) 1996-12-23 2001-07-10 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての窒素を含む複素環式芳香族化合物
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO1998057934A1 (en) 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS
SK174699A3 (en) 1997-06-19 2000-08-14 Du Pont Pharm Co Inhibitors of factor xa with a neutral p1 specificity group
IL136637A0 (en) 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
CA2321538A1 (en) 1998-03-27 1999-10-07 Dupont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
DE19845153A1 (de) * 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
ES2232202T3 (es) 1998-12-23 2005-05-16 Bristol-Myers Squibb Pharma Company Heterobiciclos que contienen nitrogeno como inhibidores del factor xa.
DE19900471A1 (de) * 1999-01-08 2000-07-13 Merck Patent Gmbh Imidazo[4,5c]-pyridin-4-on-derivate
DE60011430T2 (de) 1999-07-16 2005-07-07 Bristol-Myers Squibb Pharma Co. Stickstoff enthaltende heterobicyclen als factor xa inhibitoren

Also Published As

Publication number Publication date
NZ523184A (en) 2004-06-25
JP2004501918A (ja) 2004-01-22
CN1439008A (zh) 2003-08-27
US20020119986A1 (en) 2002-08-29
WO2002000655A1 (en) 2002-01-03
US6506771B2 (en) 2003-01-14
MXPA02012895A (es) 2003-05-14
DE60130555T2 (de) 2008-06-19
AU2001268712A1 (en) 2002-01-08
ATE373655T1 (de) 2007-10-15
CA2410393A1 (en) 2002-01-03
ES2290150T3 (es) 2008-02-16
DE60130555D1 (de) 2007-10-31
EP1296982A1 (en) 2003-04-02
EP1296982B1 (en) 2007-09-19
IL152916A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
ECSP055525A (es) Inhibidores de cinasas de tirosina
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
BR0109703A (pt) Derivados de piperazina
WO2005032472A3 (en) Pyrrolidine and piperidine derivatives as factor xa inhibitors
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
BR0317715A (pt) Composições e processos de uso de collajolie
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR9912109B1 (pt) compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto.
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
AU2003250471A1 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]